retatrutide safety trial results There is a new weight loss shot moving through trials and the numbers are bigger than anything we have seen. It is called Retatrutide. At the highest dose people lost 30 percent Early trial data for retatrutide

it's about rewriting the biological software that leads to chronic disease

Week 1 The starting dose is intentionally low

Two months later, Novo Nordisk terminated the partnership because Hims continued to sell its own compounded GLP-1 drugs alongside Wegovy

Contributing: Reuters This article originally appeared on USA TODAY: Novo to cut Ozempic and Wegovy prices amid intense competition Reporting by Ken Alltucker, USA TODAY / USA TODAY USA TODAY Network via Reuters Connect

Women of childbearing potential should discuss contraception and pregnancy planning with their GP before starting any medicine in this drug class

In the MASLD (metabolic dysfunction-associated steatotic liver disease) trial, retatrutide reduced liver fat by up to 82.4% at the 12mg dose level